Spiriva is a once-daily inhaled medication used to treat chronic obstructive pulmonary disease (COPD) and asthma. It works by relaxing the muscles around your airways so they stay open, making it easier to breathe throughout the day. Spiriva is not a rescue inhaler. It’s a maintenance treatment you use every day to prevent symptoms, not to stop an attack that’s already happening.
COPD: The Primary Use
Spiriva’s original and most common use is the long-term maintenance treatment of COPD, which includes both chronic bronchitis and emphysema. It’s FDA-approved for two specific purposes in COPD patients: easing the airway tightening (bronchospasm) that makes breathing difficult, and reducing exacerbations, those flare-ups where symptoms suddenly get much worse and can land you in the hospital.
For COPD, Spiriva is available as the HandiHaler, a dry-powder inhaler that delivers 18 micrograms per dose. You inhale it once a day, typically at the same time each morning. Because it’s a maintenance drug, the benefits build over days and weeks of consistent use. Missing doses or using it sporadically reduces its effectiveness.
Asthma: The Second Approved Use
Spiriva is also approved as a maintenance treatment for asthma in patients 12 years and older. For asthma, it comes in the Respimat form, a soft-mist inhaler that delivers 2.5 or 5 micrograms per dose. This is a different device and a much lower dose than the HandiHaler used for COPD, though the active ingredient is the same.
In asthma, Spiriva is typically added on top of other controller medications like inhaled corticosteroids when those alone aren’t keeping symptoms under control. It’s not meant to replace a steroid inhaler. Instead, it gives your airways an extra layer of protection by working through a completely different mechanism. Safety and effectiveness have not been established in children under 12 for this indication.
How Spiriva Keeps Airways Open
Your airways are lined with smooth muscle that can tighten or relax in response to chemical signals. One of those signals comes from a molecule called acetylcholine, which binds to receptors on airway muscle cells and tells them to contract. In COPD and asthma, this tightening response is often exaggerated, leaving you short of breath.
Spiriva blocks the specific receptors (called M3 receptors) that acetylcholine uses to trigger airway constriction. What makes Spiriva unusual compared to older medications in the same class is how long it stays attached to those receptors: roughly 30 hours. That’s why one dose a day is enough to maintain open airways around the clock. It detaches from other receptor types much faster (around 3 hours), which helps limit unwanted effects elsewhere in the body.
HandiHaler vs. Respimat
Spiriva comes in two inhaler devices, and they’re not interchangeable. The HandiHaler is a dry-powder inhaler approved for COPD. You load a capsule into the device, pierce it, and breathe the powder in. It delivers 18 mcg per inhalation. The Respimat is a soft-mist inhaler that produces a slow, gentle spray, making it easier to inhale for people who can’t take a sharp, deep breath. It delivers either 2.5 or 5 mcg and is approved for both COPD and asthma.
Clinical trials comparing the two devices in COPD patients found that the Respimat at 5 mcg and the HandiHaler at 18 mcg produce similar improvements in lung function, safety, and drug levels in the body. The large difference in dose numbers reflects how each device delivers medication to the lungs, not a difference in strength.
Common Side Effects
Dry mouth is the most frequently reported side effect of Spiriva and the one you’re most likely to notice. It happens because the same type of receptor Spiriva blocks in the airways also exists in salivary glands. For most people this is mild and manageable with regular sips of water.
Other side effects that show up in clinical data include upper respiratory tract infections, sore throat, headache, and cough. These tend to occur at relatively low rates and overlap significantly with symptoms people experience from their underlying lung disease. Constipation and urinary difficulty can also occur, since the drug’s receptor-blocking action can affect the gut and bladder.
Because Spiriva reduces the activity of certain nerve signals, people with narrow-angle glaucoma or an enlarged prostate should be cautious. The medication can potentially worsen eye pressure or make it harder to urinate. If you have either condition, that’s a conversation worth having with whoever prescribes the inhaler.
Cardiovascular Safety
Earlier concerns about heart-related risks with the Respimat inhaler led to a large safety trial called TIOSPIR, which followed over 17,000 COPD patients for approximately 3.5 years. The trial found that the rate of major cardiovascular events (heart attacks, strokes, and cardiovascular deaths) was 3.9% in the Respimat group compared to 3.6% in the HandiHaler group, a difference that was not statistically significant. An FDA advisory committee voted 9 to 4 that previous safety concerns, including mortality, had been adequately addressed. A small numerical uptick in heart attacks in the Respimat group (1.3% vs. 0.9%) didn’t reach statistical significance but was noted by the dissenting committee members.
What Spiriva Does Not Do
Spiriva does not work fast enough to help during an acute breathing emergency. If your airways suddenly tighten and you can’t breathe, you need a rescue inhaler, not Spiriva. It also does not treat the underlying inflammation of COPD or asthma on its own. In asthma especially, it’s used alongside anti-inflammatory medications, not as a replacement for them.
Spiriva won’t reverse lung damage that has already occurred. In COPD, the disease progressively destroys lung tissue, and no current medication can rebuild it. What Spiriva does is slow the rate of symptom worsening, reduce the frequency of flare-ups, and help you breathe more easily on a daily basis. For many people with COPD or poorly controlled asthma, that translates to fewer hospitalizations, better exercise tolerance, and a noticeable improvement in quality of life.